Production (Stage)
Foghorn Therapeutics Inc.
FHTX
$4.32
-$0.22-4.85%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 108.40% | -63.42% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 108.40% | -63.42% | |||
| Cost of Revenue | 5.45% | -16.93% | |||
| Gross Profit | 11.21% | -4.57% | |||
| SG&A Expenses | 13.95% | -8.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.46% | -15.16% | |||
| Operating Income | 4.55% | -0.64% | |||
| Income Before Tax | 3.43% | -1.99% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 3.43% | -1.99% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.43% | -1.99% | |||
| EBIT | 4.55% | -0.64% | |||
| EBITDA | 4.98% | -0.54% | |||
| EPS Basic | 3.38% | -1.57% | |||
| Normalized Basic EPS | 3.40% | -1.57% | |||
| EPS Diluted | 3.38% | -1.57% | |||
| Normalized Diluted EPS | 3.40% | -1.57% | |||
| Average Basic Shares Outstanding | -0.04% | 0.43% | |||
| Average Diluted Shares Outstanding | -0.04% | 0.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||